People · Operator

Mark S. Miller

Named in public records as an officer, director or promoter · active 2016–2021 · Biotechnology

1
Companies
6
Filings
$6.5M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
BirchBioMed Inc.BiotechnologySeries A$6.5M$571K2016
Operator network

Mark S. Miller at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Mark Miller · 18 companies · 1 sharedMark MillerHerve Girsault · 2 companies · 1 sharedHerve GirsaultJOSEPH C. SARDANO · 2 companies · 1 sharedJOSEPH C. SARDANORichard J. Shaw · 2 companies · 1 sharedRichard J. ShawTeresa Bair · 2 companies · 1 sharedTeresa BairCarlos Camozzi · 1 companies · 1 sharedCarlos CamozziCharles Ellis · 1 companies · 1 sharedCharles EllisCharles N. Ellis · 1 companies · 1 sharedCharles N. EllisJohn Verbeck · 1 companies · 1 sharedJohn VerbeckJon M. Verbeck · 1 companies · 1 sharedJon M. VerbeckJoseph Sardano · 1 companies · 1 sharedJoseph SardanoRyan V. Hartwell · 1 companies · 1 sharedRyan V. HartwellSusan Elliott · 1 companies · 1 sharedSusan ElliottSusan M. Elliott · 1 companies · 1 sharedSusan M. ElliottTeresa S. Bair · 1 companies · 1 sharedTeresa S. BairBirchBioMed Inc. · $6.5M raisedBirchBioMed Inc.Mark S. MillerMM
Mark S. Miller Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Mark S. Miller on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Mark Miller118
JOSEPH C. SARDANO12
Richard J. Shaw12
Teresa Bair12
Herve Girsault12
Joseph Sardano11
John Verbeck11
Charles N. Ellis11
Teresa S. Bair11
Charles Ellis11
Carlos Camozzi11
Susan Elliott11
Susan M. Elliott11
Ryan V. Hartwell11
Jon M. Verbeck11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.